ARCHIVES

Wilms’ Tumor Survivors At High Risk Of Heart Failure

This article is from The Cancer Letter archive.

Vol. 24 No. 4 | April 27, 2001

Download PDF Visit The Full Archive

Related Articles

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

November 28, 2014

FTC Report Disagrees With Key Provision Of Biologics Bill Backed By Companies

June 12, 2009

Blood Vessel Growth Inhibitor May Be Tested Against KS

August 16, 1991

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

January 28, 2011

Risk of Breast Cancer Recurrence Reduced With Letrozole, International Study Finds

October 31, 2003

High Response Rate of Hairy Cell Leukemia Patients to Immunotoxin Treatment In Phase I

April 27, 2001